Cibenzoline is an imidazoline derivative with antiarrhythmic properties. It is rapidly absorbed after oral administration. The bio-availability is nearly 100%. The drug half-life is between 4 and 7 hours. The drug depresses left ventricular contraction and increases systemic vascular resistance. Cibenzoline has been shown to decrease the maximal rate of rise of depolarisation in isolated cardiac fibers. The duration of action potential is increased. Voltage-clamp studies have shown a reduction in the fast sodium and in the slow currents. The following clinical electrophysiological effects have been observed: an increase in QRS duration, in AH and HV intervals and in the effective ventricular refractory period. This compound has been shown to be effective in preventing atrial arrhythmias, in suppressing reciprocating intranodal tachycardias and tachycardias associated with the Wolff-Parkinson-White syndrome and in the treatment of ventricular arrhythmias (especially extrasystoles and non-sustained ventricular tachycardia). Side effects are rare.
西苯唑啉是一种具有抗心律失常特性的咪唑啉衍生物。口服给药后迅速吸收。生物利用度接近100%。药物半衰期在4至7小时之间。该药物可抑制左心室收缩并增加全身血管阻力。已证明西苯唑啉可降低离体心脏纤维的最大去极化速率上升。动作电位持续时间延长。电压钳研究表明快速钠电流和慢电流减少。观察到以下临床电生理效应：QRS时限、AH间期和HV间期以及有效心室不应期增加。已证明该化合物在预防房性心律失常、抑制结内折返性心动过速和与预激综合征相关的心动过速以及治疗室性心律失常（尤其是早搏和非持续性室性心动过速）方面有效。副作用罕见。
